24/7 Market News Snapshot 25 November, 2024 – Citius Pharmaceuticals Inc. Common (NASDAQ:CTXR)

November 25, 2024

DENVER, Colo., 25 November, 2024 (247marketnews.com) – (NASDAQ:CTXR) are discussed in this article.
Citius Pharmaceuticals Inc. (CTXR) is experiencing a notable surge in pre-market trading, currently priced at $0.178, marking a significant increase of 33.03% from the previous day’s close of $0.134. This surge is driven by a trading volume of 15.57 million shares, indicating a robust interest among investors and showcasing confidence in the company’s future potential. The enthusiasm surrounding CTXR may set the stage for continued upward momentum as it progresses with its innovative pharmaceutical offerings.

In a related development, Citius Pharmaceuticals has successfully concluded a productive in-person Type C meeting with the U.S. Food and Drug Administration (FDA) regarding its novel product, Mino-Lok®. This catheter lock solution is designed to combat central line-associated bloodstream infections (CLABSI) and catheter-related bloodstream infections (CRBSI), addressing critical healthcare challenges. The meeting followed a successful pivotal Phase 3 clinical trial, during which the FDA provided valuable feedback concerning the drug’s clinical trial data and the pathway for a future New Drug Application (NDA) submission.

Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals, expressed optimism in light of the FDA’s constructive engagement, emphasizing the agency’s feedback as a validation of the company’s commitment to developing Mino-Lok. The innovative solution not only aims to enhance patient care by offering an alternative to catheter removal but also holds the potential to significantly reduce costs for healthcare systems.

Citius remains dedicated to advancing Mino-Lok along with its other products, including LYMPHIR™, which has recently received FDA approval, and CITI-002 (Halo-Lido). The company is committed to keeping stakeholders updated on further regulatory and clinical advancements. With Mino-Lok on track for potential approval, Citius Pharmaceuticals is well-positioned to revolutionize treatment for patients requiring catheterization, addressing a significant unmet medical need in critical care.

Related news for (CTXR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.